Sale Speculation Begins As MGI Pharma Considers ‘Strategic Alternatives’
This article was originally published in The Pink Sheet Daily
Executive Summary
Carl Icahn’s recent purchase of more than 600,000 shares feeds the rumor mill.
You may also be interested in...
Carl Icahn Pitches Nominees for Biogen Idec Board
In a letter to shareholders, billionaire investor says his slate of candidates would consider a credible bid for the company.
Carl Icahn Pitches Nominees for Biogen Idec Board
In a letter to shareholders, billionaire investor says his slate of candidates would consider a credible bid for the company.
Eisai Surprise Winner in MGI Auction
Everyone knew that MGI Pharma was up for sale, but few expected mid-cap Japanese firm Eisai to emerge victorious. Eisai pushed its offer up to $41-per-share, all cash, even though there was only one other, non-definitive, offer on the table. The $3.3 billion deal nabs Eisai two records: the largest foreign acquisition by any Japanese pharma, and the year's largest specialty pharma purchase.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: